Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–33 of 33 matching trials from the live ClinicalTrials.gov search.
Conditions
Parkinson's Disease Dementia
Interventions
Rivastigmine capsule, Rivastigmine transdermal patch
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years to 85 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Reseda, California + 14 more
Conditions
Anticholinergic Toxicity
Interventions
Rivastigmine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
10 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial

NCT00835159
Conditions
Delirium, Postoperative Cognitive Dysfunction
Interventions
Rivastigmine Patch, Placebo Patch
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Conditions
Alzheimer's Disease, Central Nervous System Diseases
Interventions
EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Comparator: Placebo, Donepezil, Rivastigmine
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Diego, California • Hallandale, Florida • Berlin, New Jersey + 1 more
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 1 Interventional Accepts healthy volunteers

Rivastigmine For Methamphetamine Dependent Individuals

NCT00158210
Conditions
Substance-Related Disorders
Interventions
Rivastigmine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Alzheimer's Disease
Interventions
Rivastigmine
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Alzheimer's Disease, Dementia, Alzheimer Type
Interventions
rivastigmine transdermal patch
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
22
States / cities
Orange, California • San Francisco, California • Boca Raton, Florida + 19 more
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Heat on Rivastigmine TDS Products

NCT03915626
Conditions
Bioavailability
Interventions
Rivastigmine (RLD) transdermal patch, Rivastigmine (generic) transdermal patch
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland